ResMed Inc. 10-Q Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 2003, and the six-month period ended on the same date. ResMed Inc. designs, manufactures, and markets devices for the evaluation and treatment of sleep-disordered breathing, primarily obstructive sleep apnea. Manufacturing operations are located in Australia, Germany, and the United States, with major distribution sites globally.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2003 | Six Months Ended Dec 31, 2003 |
|---|---|---|
| Net Revenue | $82.3 million | $155.2 million |
| Gross Profit | $52.4 million (64% margin) | $99.6 million (64% margin) |
| Net Income | $14.2 million | $26.4 million |
| Diluted EPS | $0.40 | $0.75 |
| Cash and Cash Equivalents | $107.5 million (as of Dec 31, 2003) | |
| Operating Cash Flow (6 months) | $26.0 million | |
| Long-Term Debt | $113.3 million (Convertible subordinated notes) | |
| Working Capital | $197.4 million |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 26% for the quarter and 25% for the six-month period compared to the prior year. Growth was driven by increased unit sales of flow generators and accessories, as well as favorable currency translation effects (approx. $5.8 million for the quarter).
- Profitability: Gross profit increased 25% for both periods. Margins remained stable at 64%, as favorable product mix offset higher manufacturing costs due to a stronger Australian dollar.
- Expenses: Selling, general, and administrative (SG&A) expenses rose 23% (quarter) and 24% (six months), primarily due to increased personnel and currency impacts. Research and development (R&D) expenses increased 40% (quarter) and 39% (six months) due to higher personnel costs and clinical trials, also impacted by currency.
- Balance Sheet: Inventories increased 25% to $56.9 million, reflecting higher sales volumes and a strategic build-up prior to relocating the Australian manufacturing facility. Accounts receivable improved to 63 days outstanding from 68 days.
Outlook, Risks, and Management Commentary
- Capital Expenditures: Significant spending ($27 million for the six months) is directed toward the construction of a new manufacturing facility in Sydney, Australia, expected to be operational in the first half of calendar 2004.
- Share Repurchases: The company repurchased 471,004 shares for $19.0 million during the six-month period. Total treasury stock held is 886,369 shares at a cost of $30.4 million.
- Legal Proceedings: Major patent litigation with Respironics and Fisher & Paykel Healthcare was settled in September 2003, with all claims dismissed with prejudice.
- Risks: Key risks include foreign currency exchange rate fluctuations (significant exposure to Australian Dollar and Euro), reliance on third-party reimbursement, regulatory approvals (FDA), and supply chain disruptions from single-source suppliers.
- Guidance: Management expects to continue spending approximately 8% of revenues on R&D for the remainder of the fiscal year.
Investor Verification Checklist
- Verify the impact of the Australian dollar strength on future gross margins given the majority of manufacturing costs are incurred in Australia.
- Monitor the timeline and cost overruns associated with the new Sydney manufacturing facility relocation.
- Assess the sustainability of the 26% revenue growth rate in the context of market saturation and competitive pricing pressures.
- Review the status of the microMESAM diagnostic screening device, expected for release in the third quarter of fiscal 2004.
- Confirm the company's ability to maintain current working capital levels amidst increased inventory builds and capital expenditures.